{"id":"NCT00645099","sponsor":"Janssen-Cilag International NV","briefTitle":"A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia","officialTitle":"A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-04","completion":"2009-04","firstPosted":"2008-03-27","resultsPosted":"2010-07-29","lastUpdate":"2014-05-08"},"enrollment":462,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"olanzapine","otherNames":[]},{"type":"DRUG","name":"paliperidone ER","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this 6 month study is to compare the metabolic effects of paliperidone ER and olanzapine in patients with schizophrenia, using the ratio of the concentration of lipids (triglycerides (TG)) in the blood to the concentration of good cholesterol (high density lipoproteins (HDL)) in the blood as the primary parameter. Approximately 456 adult patients will participate in this study.","primaryOutcome":{"measure":"Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio)","timeFrame":"Baseline to End Point (up to 6 months)","effectByArm":[{"arm":"Paliperidone ER","deltaMin":-0.08,"sd":1.1},{"arm":"Olanzapine","deltaMin":0.42,"sd":1.19}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"},{"comp":"OG000","p":"0.4718"},{"comp":"OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":46,"countries":["Argentina","Egypt","Estonia","France","Greece","Jordan","Latvia","Lebanon","Lithuania","Romania","Slovakia","South Africa","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=50&filename=CR013189_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":239},"commonTop":["Weight increased","Somnolence","Insomnia","Headache","Anxiety"]}}